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ABSTRACT
DETECTION OF UNIQUE TUMOR-ASSOCIATED PROTEINS IN THE 
URINE OF PATIENTS WITH TRANSITIONAL CELL CARCINOMA BY HIGH 
RESOLUTION TWO-DIMENSIONAL POLYACRYLAMIDE GEL ELECTROPHORESIS
Robert David Lehman 
Old Dominion University, 1979 
D irec to r: Dr. George L. W right, Jr., Ph.D.
A two-dimensional polyacrylam ide gel e lectrophoretic  technique was 
developed fo r the detection of unique tumor-associated proteins in urine of 
patients w ith  transitiona l ce ll carcinoma (TCC) o f the urinary bladder. This 
technique yielded high resolution o f polypeptides in the urine o f cancer patients. 
Urine was chosen as a source of tumor-associated components because the 
location o f the tum or should release already solublized tum or substances in to  the 
urine.
U rinary proteins were concentrated and then analyzed by the tw o- 
dimensional e lectrophoretic  technique using isoe lec tric  focusing in the f ir s t  
dimension and sodium dodecyl su lfa te - polyacrylam ide gel electrophoresis in the 
second dimension. Ten transitiona l ce ll carcinoma patients, ten renal cell 
carcinoma patients, two benign bladder patients, tw o benign kidney patients, and 
seven normal donors were included in this study. U rinary proteins tha t were 
associated w ith  transitiona l ce ll carcinoma and not found in normal urine or urine 
from  patients w ith  benign diseases are described.
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CHAPTER I 
INTRODUCTION
One of the princip le  problems associated w ith  an e ffe c tive  trea tm ent of 
human cancer is the fa ilu re  to  detect a neoplasm in the earliest stages of 
development. Failure to  diagnose the presence of the neoplasm early usually 
results in  metastasis (spreading of the cancer to  secondary sites throughout the 
body). Should the malignant growth be detected a t its  prim ary organ s ite , the 
chances fo r remission fo llow ing  therapeutic trea tm ent increase dram atica lly.
The fie ld  o f immunology o ffe rs  one o f the greatest potentia ls fo r im proving 
the chance of early detection o f neoplastic growth using specific  and sensitive 
immunoassays. To develop a sensitive and specific  immunodiagnostic test, a 
component, namely a tumor-associated antigen (TAA) or antibody must be 
detected, characterized, and highly purified. Tumors ac tive ly  growing in vivo 
produce recognizable histopathologic tumor-associated antigens tha t may be 
tested bio logically. As tumors grow, more TAA is released in to  the surrounding 
medium. TAAs have been described fo r  most human tumors, including bladder 
tumors by the use of in v itro  immunological tests. Nevertheless, none o f the 
TAAs have been su ffic ie n tly  purified  or characterized to  meet the c r ite r ia  fo r 
use in a diagnostic test.
The task of purify ing  a tumor-associated antigen is : d if f ic u lt  one and 
involves several problems tha t must be overcome: (1) there is no standard
source fo r  TAA. Extracts have been prepared using fresh surgical specimens, 
prim ary and m etasta tic  tum or tissue, cultured human tum or cells, serum
1
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
2components, and urine from  cancer patients. However, the preparation o f 
antigen from  these sources results in  marked v a r ia b ility  in specific  
immunological a c t iv ity  from  specimen to  specimen. (2) The antigens must be in 
soluble form  fo r  immunoassays. Such so lubiliza tion procedures may e ithe r 
inactiva te  the antigen or fa il to  ex trac t the tum or antigens. (3) The crude 
extracts contain a wide va rie ty  of "norm al" and fe ta l antigens in addition to  the 
TAA, thereby, making detection and pu rifica tion  of the la tte r  extrem ely 
d if f ic u lt .  (^) I t  is d if f ic u lt  to  determ ine i f  the test is measuring a specific  
reaction against tum or antigen, v ira l antigen, or normal antigens. F ina lly  (5), 
urine has proteins o f normal orig in  as well as proteins from  pathologic changes. 
Urine; however, should be a source of already solubilize unique components 
associated w ith  genitourinary tra c t cancer.
Because prote in components soluble in the urine seem to  be closely re la ted 
to  pathologic changes in the urogenital system, many a ttem pts have been made 
to  analyze, purify  and id e n tify  urinary polypeptides (i.e. esterases, glycoproteins, 
etc.). Results from  im munologic testing fu rth e r suggest the presence of tum or 
antigen in urine from  cancer patients. Therefore, i t  is tem pting to  speculate 
tha t the urine from  patients w ith  bladder cancer contain cancer re lated 
substances, possibly TAA.
In an a ttem pt to  enhance the id en tifica tio n  o f unique proteins in the urine of 
cancer patients, a two-dimensional polyacrylam ide gel e lectrophoretic  technique 
was used in this study. This procedure employs isoe lectric  focusing in the f ir s t  
dimension and polyacrylam ide gel electrophoresis in the presence o f sodium 
dodecyl sulfate in the second dimension. Approxim ate ly 125-i 50 polypeptides 
may be resolved using th is technique employing pro te in -specific  stains. The 
protein-stained gels are then observed fo r  any unique "spots" in the separated 
bladder cancer patient urine. Polypeptides seen in trans itiona l ce ll carcinoma 
patients but not observed in normal, benign kidney, benign bladder, or renal ce ll
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
3carcinoma patients are discussed and characterized according to  isoe lectric  
points, m olecular weights, and concentrations in  the urine sample. The tw o - 
dimensional p ro file  may, the re fo re , be used as a means of characteriz ing unique 
urinary proteins present in urine from  patients w ith  bladder cancer based on 
overall pa tte rn  d ifferences and/or s im ila rities .
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CHAPTER II 
REVIEW OF THE LITERATURE 
Biology O f U rogenita l Cancer
In the past f iv e  years, great strides have resulted in increased contro l and 
maintenance of genitourinary tumors. Transitional cell carcinoma (TCC) or 
bladder cancer is responsible fo r  approxim ate ly 4% of new cancer cases per year 
in the U n ited States population w ith  an occurrence of 13 cases/100,000 
population. This highly invasive malignancy ranks second to  p rosta tic  cancer as 
the most frequent urogenita l tum or and occurs most commonly in the male w ith  
an approxim ate th ree fo ld  greater incidence in males than in females (110). The 
l i fe  hisory and aggressiveness o f the tum or is quite diverse and unpredictable 
sometimes recurring quite  frequently  in some patients and rare ly  recurring in 
other cancer patients (32). As w ith  renal ce ll carcinoma (RCC), TCC f irs t  
demonstrates its e lf by gross or m icroscopic hem aturia (22, 85, 110). To date, 
cystoscopy is the d e fin itive  diagnostic procedure (33). Increased local thickening 
of the bladder wall may be seen at the prim ary s ite  of bladder carcinoma (38).
The "stage" of the cancer re flec ts  the aggressive nature and loca liza tion  of 
the tum or w ith in  various organs of the body. The stage is very im portan t in the 
complete diagnosis of the cancer patient. The Jew ett staging fo r  TCC (59) is 
shown in Table 1 and the staging fo r  RCC (55) is demonstrated in Table 2. A 
neoplastic tum or confined to  the dome of the bladder (4 cm or less) and classified 
as stage O, A, or B may be elim inated fa ir ly  easily by surgery. I f  the neoplasm 
has not metastasized to  the lymph nodes, cure is possible (22). Appendix A shows 
d iagram m atica lly the advancement of the neoplasm in to  the bladder wall.
4
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5TABLE 1
STAGING OF TRANSITIONAL CELL CARCINOMA TUMOR INVASION
STAGE TUMOR INVASION
O Pre-invasion. Carcinoma in situ in a f la t  
or papillary form  which does not pene­
tra te  the basement membrane
A Neoplasm penetrates basement membrane 
in to  submucosa but does not invade the 
muscle
B In filtra tio n  of the superfic ia l muscle
r In filtra tio n  of deep muscle and perivascular 
fa t
D1 Extension in to  adjoining organs (e.g. 
pelvic side wall, prostate, vagina, 
lower anterior abdominal wall)
D2 Metastasis to nodes and viscera
From Jew ett: J. o f Urol. 55:366-372 (1946).
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6TABLE 2
STAGING OF RENAL CELL CARCINOMA TUMOR INVASION
STAGE TUMOR INVASION
FIVE YEAR 
SURVIVAL RATE
A1 Tumor is encapsulated 
No renal parenchyma invasion
85%
A2
Tumor capsule broken 
Renal parenchyma invasion 
No lym phatic  or venous invasion 
Renal capsule in ta c t
60-70%
B
Kidney capsule invasion
Perirenal fascia invasion
Perinephric fa t  invasion
M icroscopic lym phatic and venous invasion
C l Invasion o f perinephric fascia 
Involverr ent of renal vein or in fe rio r 
vena cava
30%
C2 Gross lym phatic invasion 20%
D D istan t metastasis usually to  lung 
bone or brain 10%
From: Holland J.M. Cancer 32:1030-1042 (1973).
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7Appendix B demonstrates the staging of RCC. Radical cystectom y fo llow ed by 
radiation therapy is the choice of in it ia l trea tm en t fo r tumors o f high stage 
(stage C and D) cancers. Carcinoma m situ  is trea ted  by radiation therapy pre- 
operatively (110). Catalona (18) warns against extensive operations or rad ia tion 
therapy because th is  trea tm ent may result in depression o f immunological 
re a c tiv ity  to  the invading tum or. He reports im paired host immunocompetence 
in 100% o f patients w ith  stage C and D tumors and 27% im pairm ent in stage A 
and B tumors.
Malignancy is the a b ility  o f cells to  grow progressively in vivo and lends 
itse lf to  the possib ility of metastasis. The transform ation o f normal cells in to  
neoplastic cells is accompanied by major b iological a lterations. Changes include 
the appearance o f soluble antigens tha t previously were not present in normal 
cells (1, 15, 43, 61, 65, 79, 80). U rinary tra c t neoplasms detected in the past by 
the appearance o f cancer ceils in the urine or in the vagina (16, 70, 84) have led 
to  the use o f the routine "PAP smear" which detects neoplastic cells in the 
urogenital tra c t. This method of detection, although diagnostic, is not the 
preferred method as cancer cells are sometimes not discovered un til metastasis 
has occurred.
Immune Response to  Tumors
The immune system is an extrem ely complex array of molecular and ce llu la r 
functions tha t are conceptionally d is tinct. The ce ll-m ediated immune system is 
derived from  thymus-processed lymphocytes (T-celJ) whereas the humoral 
immune system lymphocytes (B -cell) are thought to  o rig inate  from  bone-marrow 
stem cells. The immune system may be manipulated to  the benefit of the cancer 
patient (122). There is evidence tha t the T-and B-lymphocytes must act together 
fo llow ing appropriate antigenic stim ula tion to  fu lly  express the immune response 
needed to  defend the body against bladder cancer (49, 83, 90).
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8Antigens may be o f normal orig in  term ed h is tocom pa tib ility  antigens (HL-A) 
such as species-specific, tissue-specific , and organ-specific antigens; or may be 
v ira l, bacteria l o r tum or-spec ific  antigens (102). The human body e lic its  an 
immunological response to  antigens fore ign to  its e lf  by increasing 
immunoglobulin levels, and by ac tiva ting  the T-and B-cell populations. As the 
tumor size and invasive properties increase, immunocompetence decreases to  the 
point th a t the body is overcome by the tumor mass; there fo re , m onitoring of 
immunological components, namely TAA or tumor-associated antibodies, in 
cancer patients is extrem ely im portan t during the course o f cancer trea tm ent. 
Recognizable h istopathologic TAAs are produced by the ac tive ly  growing 
neoplasm and the re fo re  the la rger the tum or size, the more cells e lic it  the TAA 
(40, 61). Reducing tum or size yields an increased anti-TC C  cell-m ediated 
im m unity during adm in istra tion  of Bacille  Calm ette-G uerin, an adjuvant used to  
increase the responsiveness of the immune system to  the tum or (50).
U rinary Proteins
Detection o f unique components in complex b io logical flu ids such as urine is 
a major techn ica l problem. Urine was chosen as a source o f unique proteins 
associated w ith  bladder cancer because the loca tion  of the tumor w ith in  the 
bladder should release already soluble tum or components in to  the urine. 
Antigens, being spec ific  ce ll-surface immunological determ inants, are shed in to  
the surrounding medium; therefore , the urine should be a natural reservoir of 
these tum or components. Several reports describe the a typ ica l nature o f the 
urine o f cancer patients compared w ith  the urine o f normal patients (14, 22, 46, 
91, 109, 113, 127). The urine o f normal patients contains 60-80 m g /lite r of 
colloids, o f which 60% are proteins and is termed "physiological pro te inuria" (53, 
54). Th irty-one proteins have been isolated in the urine tha t may also be found in 
the blood o f normal patients (11). These proteins include polypeptides such as
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
9h is tocom patib ility  antigens (97), esterases and other enzymes (31, 53, 123), and 
glycoproteins (30). G rant describes tw e lve  non-plasma proteins which orig inate  
in the kidney, ure ter, urinary bladder, urethra, and prostate (45). A tten tion  has 
been spec ifica lly  focused on the significance o f non-plasma tissue proteins in the 
urine excretion called "h is tu ria " (5) o f which the kidney and bladder are the most 
d irec t and obvious sources (46).
D etection O f Protein Abnorm alities In U rine O f Cancer Patients
Cancer patients have abnormal excretion of polypeptides both quan tita tive ly  
and qua lita tive ly  as compared to  the prote in content in the urine of normal 
patients (14, 109, 112). The content of proteins in the urine changes w ith  the 
growth and development o f particu la r neoplasms. Rudman, e t. al. (109) have 
reported increased excretion o f polypeptides between the range 12,000 -  50,000 
daltons in patients w ith  advanced neoplasms and have a ttr ib u te d  these proteins 
to  the tum or tissue ra ther than to  abnormal tubular reabsorption or defective 
perm eability  o f an impaired glomerulus. They suggested th a t the increased 
excretion of these proteins was responsible fo r  pathological prote inuria . D e fin ite  
corre lations between damage in the urogenital system and m olecular size of 
proteins excreted is well established. The excretion o f high m olecular weight 
proteins (e.g. large amounts of albumin, and transfe rrin ) are characte ris tic  of 
glom erular damage whereas tubular dysfunctions are associated w ith  the 
e lim ination of small amounts o f albumin and low molecular weight molecules 
(e.g. immunoglobulin lig h t chains, lysozyme, 3-2 m icroglobulin) (10, 29, 87, 88, 
99, 112). Although the protein content and protein p ro file  are variable w ith  each 
urogenital disorder, the prote inuria  often is caused by hemoglobin in  the urine. 
Hemoglobin is the most common ind ication o f cancer of the kidney, renal pelvis, 
ure ter (68), bladder (39), or prostate (21). Gross hematuria is reported in over 
50% of a ll RCC cases. Diseases in neighboring organs can cause hem aturia by
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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the invasion o f urinary structures (e.g. cancer o f the uterus, vagina, o r colon). 
Detection o f Tumor Components
The detection o f TAA is po ten tia lly  the most re liable approach to  
immunodiagnosis of a malignancy. In 1965, Gold and Freeman discovered an 
antigen tha t was present in colon carcinoma and in the fe ta l colon but absent in 
normal adu lt tissue (42). This antigen was termed the carcinoembryonic antigen 
(CEA) and was la te r found to  be present in numerous malignant tumors and not 
specifica lly  in colon carcinoma as orig ina lly  believed (47). Since the advent of 
the concept of TAA,  many immunological in v itro  tests have been developed to  
measure the a c tiv ity  of the TAA (41, 140, 142). Immunological tests such as 
leukocyte m igration inh ib ition  and leukocyte adherence inh ib ition  (6, 61, 111, 
140, 142) measure the ^ li-m e d ia te d  im m unity of cancer patients blood 
leukocytes in response to  the presence of a fore ign antigen. Leukocytes from  
bladder cancer patients are cy to tox ic  to  neoplastic bladder cells from  the ir own 
(autologous) tum or and from  other patient's tumors (allogeneic) (17) due to 
surface antigens.
Extracts containing TAAs have been isolated from  fresh surgical specimens 
(71, 81, 82), m etasta tic  tum or tissue (27, 142), serum components (52, 66, 104, 
121, 140) and urine (109, 120). Hollinshead (56) has described the partia l 
pu rifica tion  of a 40,000 dalton TAA unique to  TCC patients by gel f i lt ra t io n  and 
polyacrylam ide gel electrophoresis. Rabbit antisera specific fo r transitional cell 
carcinoma has been prepared using TAA patients w ith  this malignancy (44) and a 
pa rtia lly -pu rified  TAA was characterized and tested. W right and Sieg (141) have 
isolated a pa rtia lly  purified bladder cancer-associated antigen from  tum or cell 
extracts by gel f iltra tio n .
Review Of Electrophoresis
Many systems have been employed to  evaluate and m onitor the urinary
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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excretion (i.e. cha rac te ris tic  proteins o f cancer) in  patients w ith  renal and 
bladder cancer. A technique w idely used to evaluate complex biological flu ids is 
electrophoresis. Electrophoresis, which is the movement of e le c tr ica lly  charged 
collo id partic les under the in fluence o f an applied e lec tr ica l po ten tia l, has under­
gone numerous revisions and m odifica tions to  enhance the resolving power o f this 
method o f protein separation. Proteins, a t an appropriate buffered pH, have 
e ither a net negative or net positive charge; therefore, they can be made to  
move toward e ither the cathode (fo r postively charged proteins) o r the anode (for 
negatively charged proteins) by applied current.
In 1937, Teselius perform ed the f ir s t  crude attem pts a t electrophoresis and 
separated serum globulins in to  a,8» and y  components by "m oving boundary" 
electrophoresis (124). He la te r refined electrophoresis and introduced zone 
electrophoresis concurrent w ith  the development o f paper electrophoresis. Many 
support media were tr ie d  (e.g. gelatin) u n til Smithies introduced starch gel as a 
medium fo r support (116-118) and separated serum proteins as well as other 
protein m ixtures. Four years la te r, Davis and Ornstein (25) introduced 
pre lim inary results o f polyacrylam ide gel electrophoresis. Smithies had already 
introduced the concept of m olecular sieving in starch gels; however, Raymond 
showed conclusively tha t m olecular sieving yielded sharper zones in 
polyacrylam ide gels than in starch gels (93). Raymond fu rth e r m odified the 
e lectrophoretic procedure by in troducing a ve rtica l gel slab (94) and varied the 
concentration of the acrylam ide monomer to  achieve a desired porosity w ith in  
the gel m atrix  (96). S later (115) m odified the concept of m olecular sieving by 
varying the gel concentration and introduced the concept o f a gel concentration 
gradient where the pore size of the gel is constantly decreasing in the direction 
of m igration of the proteins. W right (133) described a gradient "d iffe re n tia l disc 
electrophoresis" in polyacrylam ide gels which fu rth e r refined the molecular siev-
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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ing e ffe c t o f the gel.
Isoelectric Focusing
Further developments in electrophoresis were pioneered in polyacrylam ide 
gels w ith  the advent o f isoe lec tric  focusing. Isoe lectric  focusing, also called 
electrofocusing, has been a successful tool o f prote in separation tha t has 
undergone various m odifica tions. Isoe lectric  focusing is a means of separation in 
which proteins are separated by electrophoresis in a starch or polyacrylam ide gel 
containing a pH gradient linea rly  d is tribu ted over the length o f the gel. Proteins 
m igrate through the pH gradient un til they reach a cha racte ris tic  point, the 
isoe lectric  point, (pi) or pH where the proteins bear no net charge; there fo re  they 
do not m igrate under an e lec tr ica l influence. The idea o f separating molecules 
by electrofocusing has been known fo r a long tim e. In 1912, Ikeda and Suzuki, 
two Japanese scientists, were granted a patent fo r a method of producing 
glutam ic acid from  plant proteins by electrofocusing (58). Though unrefined, the 
Japaneses scientists la id  down the p rim itive  methods of isoe lectric  focusing th a t 
la te r were m odified by W illiam s and Waterman (131) who used a 14-chambered 
apparatus. Gel rod disc isoe lec tric  focusing electrophoresis has been described 
(19, 48, 126, 143, 144) and involves the movement of macromolecules in a pH 
gradient to  a region of th e ir isoe lc tric  pH value (119). The pH gradient is 
produced by applying a voltage to a m ixture  o f ampholytes (am ino-carboxylic 
acids possessing a range of isoe lectric  points and ranging in molecular weight 
from  300-600 daltons) (48). P re lim inary isoe lec tric  focusing was perform ed in a 
sucrose density gradient fo r  preparative frac tiona tion  o f protein samples (23, 
128). The reagents used fo r sucrose gradients were expensive and the procedure 
was slow. Therefore, polyacrylam ide gels were introduced to  s tab ilize  the pH 
gradients.
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Two-Dimensional Electrophoresis
Two-dimensional starch gel electrophoresis was f ir s t  reported by Smithies 
and Poulik (117) fo r  separating proteins o f human serum. In 1958, they combined 
two zone e lectrophore tic  methods ( f i l te r  paper and starch gel) in the form  of 
two-dim ensional zone electrophoresis and separated, and to  some extent 
iden tified , various subfractions o f classical components tha t Tiselius described in 
his separation technique. Raymond (95) introduced acrylam ide as a support 
medium in two-dimensional electrophoresis. This technique was basically tha t of 
Smithies and Poulik; however, this means of separation of serum yielded more 
polypeptides. I t  was not u n til 1969 tha t a two-dimensional polyacrylam ide 
gradient system was used in a slab gel in which the concentration of the 
polyacrylam ide increased progressively along the length of the gel slab. Two- 
dimensional electrophoresis o f proteins yielded numerous polypeptides; however, 
because separation was based on the same parameter in both dimensions 
(molecular weight and charge properties), the proteins were distributed along a 
diagonal instead o f being randomly d istributed w ith  the gel area.
W ith the concept of two-dimensional electrophoresis established but not yet 
fu lly  developed, Kenrick and Margolis (60) described a two-dimensional system in 
which isoe lec tric  focusing was performed in the f ir s t  dimension fo llowed by 
electrophoresis in  a second dimension w ith  a gradient polyacrylam ide slab gel 
(4.596-2 696 polyacrylam ide). Because of the e -lim iting  features of the 
gradient slab gel, this combined two-dimensional system more e ffe c tive ly  
separated the proteins than e ither isoe lectric  focusing or polyacrylam ide gel 
electrophoresis (130). O 'Farre ll fu rthe r improved upon the above tw o- 
dimensional system by adding sodium dodecyl su lfa te, an ionic detergent to the 
second-dimensional gel m ixtu re ; therefore, charge differences of each protein 
are m inim ized due to  the net negative charge provided by the SCS (77, 78). Two-
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dimensioned electrophoresis has also been documented fo r the separation of 
tissue and serum components (2, 3, 4, 23, 60, 91, 117, 118, 134, 135, 138).
Wilson (132), and Anderson and Anderson (2) reported increased resolution 
and rep roduc ib ility  of two-dim ensional gel pro files by adding SDS and 8-ME to  the 
protein samples to  be separated so tha t maximal solubiliza tion could be achieved.
No two-dim ensional e lectrophore tic  technique fo r  urine using IEF in the f ir s t  
dimension and PAGE/SDS in the second dimension has been reported; however, 
electrophoresis of urine from  patients w ith  renal disease has been documented. 
Pires, e t. al. (91) have reported a one-dimensionai SDS/polyacrylamide tube gel 
e lectrophoretic  technique fo r  patients w ith  renal disease. They showed tha t 
patients w ith  glom erular diseases excreted high m olecular weight proteins; 
whereas, patients w ith  tubular damage had an abundance of low m olecular weight 
proteins in  th e ir urine. Vesterberg and Nise (127) have performed slab gel 
isoe lectric  focusing on urinary proteins from  workers occupationally exposed to  
cadmium poisoning. They showed d iffe re n tia l e lectrophoretic  p ro file  of the 
glom erular and tubular m alfunctions of the exposed and unexposed workers. 
Nery, et. al. (76) perform ed disc electrophoresis on urine o f patients w ith  
bladder cancer and showed CEA a c tiv ity  on p a rtia lly  purified frac tions. They 
described m ulti-com ponent aggregates present in the urine w ith  m olecular 
weights ranging from  less than 1000 to  several m illion  daltons.
Since electrophoresis has developed in to  a useful too l fo r  the 
characteriza tion of complex b io logical flu ids , i t  is advantageous to  incorporate 
IEF and polyacrylam ide gel electrophoresis in to  the study of proteins in the urine 
of cancer patients in hopes tha t a unique component specific to  carcinoma of the 
bladder may be found and isolated. When the component is isolated, an 
imm unological diagnostic test can be developed and used fo r the early  detection 
of th is malignancy.
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CHAPTER III 
MATERIALS AND METHODS 
U rinary P rote in E xtraction
Tw enty-four hour urine specimens were obtained from  Dr. Paul 
Schellhammer, Departm ent o f Urology of the Eastern V irg in ia  Medical School, 
and from  Dr. James Reid o f the Portsmouth Naval Hospital Departm ent of 
Special Hematology. A ll cancer patients were from  the T idewater V irg in ia  area 
and were h isto log ica lly  diagnosed and staged as having renal ce ll carcinoma 
(RCC) or transitiona l ce ll carcinoma (TCC). As controls, urine samples were 
obtained from  patients w ith  benign bladder (BB), and benign kidney (BK) tumors. 
Individual and "pooled" urine specimens from  normal employees in the 
Departm ent of M icrobiology 6c Immunology a t the Eastern V irg in ia  Medical 
School were obtained and used as controls. Table 3 is a lis t  o f urine samples 
employed in th is study. Sodium azide (NaN^) was added to  each urine sample to  
a f in a l concentration 0.02% (w /v) to  in h ib it bacteria l growth. This concentration 
o f azide was maintained throughout the preparation procedure. The urine was 
concentrated 100-150 fo ld  using a m odifica tion of the procedure o f Reisfeld (98) 
fo r  iso lating urinary h is tocom patib ility  (HL-A) antigens. A ll procedures involving 
urinary protein preparations were carried out a t 4°C to m in im ize p ro teo ly tic  
a c tiv ity .
The pH of the crude untreated urines ranged from  4.25 to  7.50. Each urine 
was adjusted to a pH of 8.0 by addition o f a 1M T ris -H C l, ph 9.0 bu ffe r to  the 
urine. The prec ip ita te  tha t often resulted was removed by centrifugation  a t 3000 
x g fo r  30 min a t 4°C and the prec ip ita te  discarded. The resulting supernatant
15
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was f ilte re d  through Whatman //2 f i l t e r  paper under reverse pressure a t 15 lb /in  . 
Solid ammonium su lfa te  was added in increments o f 100 g w ith  constant s tir r in g  
a t 4°C u n til a saturation po in t o f 80% (560 g / lite r )  was obtained. The p rec ip ita te  
was harvested by cen trifug ing  a t 20,000 x g fo r  20 m in a t 4°C . The supernatant 
was discarded and the p rec ip ita ted  proteins were co llected and transferred to  a 
dialysis bag w ith  a m olecular weight c u to ff o f 12,000 daltons. The dialysis bag 
was then placed in to  one l i te r  o f s te rile  phosphate buffered saline, pH 7.3 (PBS- 
Solution W: Appendix D) supplemented w ith  0.02% (w /v) NaN^ and placed in a 
re fr ig e ra to r a t 4°C . The PBS was changed once a day fo r  three days or u n til a ll 
o f the proteins became resuspended in solution. The presence o f sulfate ions was 
tested fo r  by adding a few  drops o f 10% B a C ^  solution to  the dialysate. I f  no 
white p rec ip ita te  was seen, ind ica ting the absence of su lfa te  ions, the proteins 
were dialyzed against two changes o f s te rile  PBS a t 4°C w ithout NaN^ and 
fu rthe r concentrated to  10 m l by u ltra f ilt ra t io n  in a s te rile  Amicon unit using a 
UM5 u ltra f ilt ra t io n  membrane having a m olecular weight c u to ff of 5000 daltons. 
The u ltra f ilt ra te  was centrifuged a t 150,000 x g a t 4° C  fo r  one hour, the 
supernatant s te rilized  by membrane f i lt ra t io n  using a s te rile  0.45 m icron 
membrane f i l te r ,  and the s te rile  urinary proteins v/ere placed in to  s te rile  serum 
bottles. Protein concentration was determined by the method o f Lowry (67) and 
urine samples stored a t -70°C fo r  la te r use.
Preparation O f U rinary Sample
Basically, the preparation o f the concentrated urinary proteins was s im ila r 
to tha t o f Wilson (132), and of Anderson and Anderson (3). Sodium dodecyl 
sulfate and 8-mercaptoethanol were added to  the urinary proteins p rio r to  
electrophoresis so tha t the fin a l concentration o f each reagent was 0.1% and 5%, 
respectively. I t  was extrem ely im portan t to keep th is m ix tu re  on ice during 
preparation to  prevent protein degradation (132).
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First-D im ensional Separation
Isoe lectric  focusing was perform ed by developing a linea r pH gradient w ith  a 
polyacrylam ide m atrix  and a llow ing the charged macromolecules to  m igrate 
through the m a trix  u n til reaching a po in t in the gel where the net charge o f each 
polypeptide equaled zero (pH=pI). Isoe lectric  focusing was carried out in glass 
tubes (150 mm x 3 mm i.d .) tha t were thoroughly cleaned w ith  7X laboratory 
detergent, soaked overnight in a 3% (v /v) solution of Photoflo (Eastman-Kodak 
Co.) and oven-dried. Three tube gels were prepared fo r  each urine sample in 
each run. Two of the tube gels were stained to  determ ine the rep roduc ib ility  in 
the f ir s t  dimension; the th ird  tube was used fo r  electrophoresis in a second 
dimension. The tubes were marked 115 mm from  the bottom , sealed a t the 
bottom  w ith  P ara film , and placed in a leve l gel tube holder. I t  was im portan t to  
keep the length o f the gel constant in a ll runs due to  the fa c t tha t v a r ia b ility  in 
the gel length produced a variab le pH gradient. To make 10 m l o f isoe lectric  
focusing m ix tu re  (enough fo r  10 tubes), the recipe in Table 4 was fo llowed 
consisting of a m ix tu re  of 9M urea, 7% acrylam ide and 2% ampholines. The urea 
was com plete ly dissolved by warm ing to  37°C at which tim e  15 y l  of ammonium 
persulfate solution (Solution C: Appendix D) and 10 y l o f TFMEO were added and 
the m ixtu re  qu ick ly but ca re fu lly  loaded in to  the glass tubes by use o f a long Pas­
teur p ipette . Care was taken not to  trap  any bubbles during the f i l l in g  of the 
tubes. The tubes were f il le d  to  the 115 mm mark and gently overlayed w ith  gel 
overlay solution (Solution D: Appendix D). The discrete in te rface  between the 
top of the gel and the overlay solution should be seen w ith in  20 min a fte r 
overlayering. Full po lym erization was accomplished w ith in  one hour a fte r the 
addition o f TEMED. A fte r  one hour, the gel overlay solution was aspirated and 
replaced w ith  20 p i of lysis solution (Solution F: Appendix D). A fte r  one hour, 
the lysis solution was aspirated, the Parafilm  removed and tubes placed in a
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TABLE 4
ISOELECTRIC FOCUSING MIXTURE
5.5 g o f u ltra  pure urea
1.35 m l o f IEF acrylam ide (Solution A: Appendix D) 
2 ml o f Nonidet P-40 (Solution B: Appendix D)
1.9 m l of Abbott Co. s te rile  d is tilled  w ater 
0.4 m l o f B io ly te  ampholine, pH range 5 to  7 
0.1 m l of B io ly te  ampholine, pH range 3 to  10
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standard tube gel e lectrophoretic chamber (Bio-Rad Model 155) equipped to  hold 
3 mm i.d. tubes. The tubes were aligned so tha t the top of the gel was positioned 
in the upper reservoir chamber. The lower reservoir was f ille d  w ith  0.01M 
H^PO^ (Solution G: Appendix D) and bubbles were removed from  under the gel 
bottom so e lec trica l contact could be made. Twenty p i of fresh lysis solution 
(Solution F: Appendix D) was added to  the gel top and overlayed gently w ith  
0.02M NaOH (Solution H: Appendix D). The upper reservoir was re fille d  and the 
gels were then pre-run at room tem perature to  develop the pH gradient. The 
schedule fo r  pre-electrophoresis was as follows: 15 min at 200 volts, 30 min at 
300 volts, and 30 min a t 400 volts (regardless o f the number of tubes). During 
this tim e, the SDS and 8-ME were added to  the urinary proteins which were kept 
on ice to  prepare them fo r electrophoresis. A fte r the pre-electrophoresis run 
was complete, the power was turned o ff, the upper reservoir emptied, and the 
overlays aspirated from  the top of the gel. A fte r  sample preparation was 
completed, the protein samples (400 yg  o f protein) were loaded onto the top of 
the gel by use of a Ham ilton m icrosyringe. The samples were then overlayed 
w ith  10 y l  o f sample overlay solution (Solution I: Appendix D). The overlay was 
care fu lly  overlayed w ith  0.02M NaOH solution so as not to "bomb" the in terface 
of the protein sample. The upper chamber was f ille d  w ith  sodium hydroxide 
solution. The gels were electrophoresed at room temperature overnight a t 500 
volts, increased to  700 volts in the morning and run fo r  one hour a t this voltage. 
A fte r th is tim e, the voltage was increased to  800 volts and continued fo r one 
additional hour. The product of volts and the tim e (in hours) to ta led 10,000 vo lt- 
hours.
Once the first-d im ensional e lectrophoretic run was complete, the gels were 
removed by f irs t  rim m ing the inside o f the IEF tube w ith  a syringe f ille d  w ith 
d is tilled  water and equipped w ith  a 21 gauge x l 'h  in needle. The needle was
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inserted between the gel tube wall and the water gently forced in to  the space 
between the gel and tube wall to  reduce fr ic tio n . A 20 m l syringe was connected 
to  the cathode end o f the tube via a short piece of Tygon tubing and the gel was 
forced out by slight pressure. Once the gel was extruded, the negative end o f the 
gel was marked by stabbing i t  w ith  a 24 gauge needle dipped in  India ink.
Equilibration Of The IEF Gel For Two-Dimensional Electrophoresis
The IEF gel was equ ilibrated by placing the gel in to  a (6 mm x 150 mm test 
tube w ith  15 m l o f SDS sample bu ffe r (Solution P: Appendix D). The tube was 
sealed w ith  Parafilm  and gently shaken at room tem perature fo r  45 min. This 
equ ilibration was necessary because the proteins tha t now have no net charge 
(due to  im m obiliza tion a t a well defined pi) must be given a charge i f  they are to  
move in a second e lectrophore tic  system.
Staining Of The F irst-D im ensional Gel
Two of the three tr ip lic a te  IEF gels were stained by f ir s t  f ix in g  the proteins 
in to  the polyacrylam ide m a trix  by placing the IEF gel in to  15 m l of f ix in g  
solution (Solution 3: Appendix D) and shaking at room tem perature fo r  one hour. 
The fix in g  solution was replaced w ith  15 m l of staining solution (Solution K : 
Appendix D) and the gels incubated a t 56°C fo r 45 min. The gels were then 
destained w ith  Solution L (Appendix D) fo r  18 hours fo llowed by replacement 
w ith  fresh destaining solution. Destaining was continued fo r  an additional 18 
hours un til the background between the protein bands was clear. The destaining 
solution was decanted and replaced w ith  IEF preserving solution (Solution V: 
Appendix D) to  preserve the gel and enhance the protein bands. Gels were stored 
a t 4°C u n til photographed or scanned by a spectrophotometer.
Measurement Of The pH Gradient
An IEF gel w ithout prote in (blank gel) was extruded from  the tube a fte r
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electrophoresis (as described above) and cu t in to  10 mm sections w ith  a scalpel. 
Each section was put in to  a 13 mm x 100 mm test tube w ith  2 m l o f A bbo tt Co. 
d is tilled  water and shaken at room tem perature fo r  one hour. The pH o f each 
tube was measured and p lo tted  as a function  of centim eters o f gel versus pH. A 
typ ica l pH gradient using the indicated percentages o f B io ly te  ampholines is 
shown in Figure 1.
Second-Dimensional Separation
Separation in the second dimension was accomplished by PAGE/SDS 
electrophoresis using a Bio-Rad Model 220 slab gel electrophoresis chamber. A 
polyacrylam ide gradient system of 1096-20% polyacrylam ide supplemented w ith  
0.1% SDS was employed in th is study. A notched beveled plate (180 mm x 1M 
mm) was used to  fa c il ita te  acceptance o f the firs t-d im ensiona l gel in to  the 
second-dimensional system (Figure 2). The glass plates were thoroughly cleaned 
w ith  70% (v/v) isopropanol solution, washed in 7X laboratory detergent, rinsed in 
d is tilled  water, soaked overnight in a 6% (v/v) Photoflo solution (Eastman-Kodak 
Co.) and oven dried. The plates were assembled w ith  Bio-Rad PVC spacers (140 
mm long x 20 mm wide x 1.5 mm) in order to  form  a gel slab o f 120 mm x 160 
mm x 1.5 mm th ick . Figure 3 shows the apparatus w ith  the beveled-notched 
plate set up so the bevel was toward the outside of the apparatus. The 
rectangular gel mold was clamped onto the apparatus tig h tly  and the bottom  of 
the mold was sealed w ith  a greased gasket. For pouring the gel gradient, a 
standard two-chambered gradient m ixer (Buchler S c ien tific  Co., Fort Lee, N.3.) 
was assembled as shown in Figure 4. The electrophoresis chamber was then 
placed on a tab le leve le r p rio r to  pouring. The gel solutions fo r  10% and 20% 
polyacrylam ide (0.1% SDS, 0.375M T ris -H C l, pH 8.8) are presented in Table 5. 
Both solutions were kept chilled during preparation o f the gel slab.
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Figure 1. D eterm ination o f pH values fo r  the firs t-d im ensiona l polyacrylam ide 
e lectrophore tic  separation. Percentages o f ampholines (Table 2) and conditions 
of electrophoresis are presented in the tex t. Cathode is toward the le f t  o f the 
graph.
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Notched plate, plain
Notched plate, beveled for 20
Rectangular plate, plain
R e c ta n g u la r p la te , g ro o v e d  fo r  20
Figure 2. Glass Plates used fo r the second-dimensional polyacrylam ide 
separation. Dimensions are in mm. From: Bio-Rad Laboratories, A p ril, 1978 
Price L is t, p. 126.
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Cooling water connector
a
Cell core
Electrode connection 0
®    Upper buffer gasket
a
Notched glass plate
Rectangular glass plate
PVC spacer
- Sealing bar gasket
Support 
sealing bar
Screws
Pressure cams
Figure 3. Apparatus used in second-dimensional polyacrylam ide gel electrophoresis. 
Glass plates (Figure 2) are clamped to the apparatus fo r  gradient polyacrylam ide 
electrophoresis. From: Bio-Rad Laboratories, A p ril, 1978 Price L is t, p. 127.
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Figure 4. Representative drawings o f the apparatus used to  pour tw o- 
dimensional gradient polyacrylam ide slab gels. Gradient m ixing chambers 
(Chamber A fo r  10% polyacrylam ide solution, Chamber B fo r  20% solution) are 
15 mm i.d. x 115 mm and are attached to  a ring stand. C is a stopcock to  
regulate the flo w  between chambers. O utflow  regulation (D); e le c tr ic  s tirring  
m otor, E (fo r m ixing the 10% and 20% solutions); drainage assembly (F); m ixtu re  
level (a and d), 12 m l mark. The T-Connector ou tflow  assemblage (H) consists of 
two b u tte rf ly  infusion needles (19 gauge x 7/8 in) (n). The needles are attached 
to  the gel mold so tha t the bevel needle touched the inside of each PVC spacer.
Gel Mold: The mold (L) is held ve rtic a lly  by the e lectrophore tic  ce ll. Exploded 
view shows assemblage of gel mold as seen in  Figure 2. PVC spacer (g) is 1.5 mm 
th ick. Dimensions o f gel mold: O uter- 180 mm x 140 mm x 10.5 mm. Inner-160 
mm x 120 mm x 1.5 mm. From: V /right, G .L., Am. 3. C lin . Path. 57(2):173-185 
(1972).
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TABLE 5
SOLUTIONS FOR TWO-DIMENSIONAL GRADIENT GELS
Ligh t Solution (10% polyacrylam ide)
3 m l o f lower gel bu ffe r (Solution N: 
Appendix D)
4 m l o f acrylam ide (Solution M:
Appendix D)
5 m l o f Abbott Co. d is tilled  water
60 y l  o f ammonium persulfate (Solution C: 
Appendix D)
6 y l  o f TEMED
Heavy Solution (2096 polyacrylam ide)
3 m l of lower gel bu ffe r (Solution N: 
Appendix D)
8 m l of acrylam ide (Solution M: 
Appendix D)
1 ml of Abbott Co. d is tilled  water
40 y l  of ammonium persulfate 
(Solution CiAppendix D)
6 y l o f TEMED
1.2 g of sucrose
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A to ta l volume of 24 ml was necessary to  produce a slab 160 mm long by 120 
mm high and 1.5 mm th ick . This volume f ille d  the apparatus to  a level 20 mm 
below the bevel of the notched plate. To avoid bubble fo rm ation , the solid 
sucrose was brought in to  solution by lig h tly  vortexing prior to  the addition of the 
lower gel bu ffe r. The 10% acrylam ide solution was poured in to  the back chamber 
(Chamber A:Figure 4) o f the gradient m ixer and the 20% acrylam ide solution was 
poured in to  chamber B as shown in Figure 4 keeping the stopcock (C) between the 
two chambers closed. The magnetic s tir re r was turned on and three ml of the 
20% acrylam ide solution was allowed to  flow  by gravita tiona l force in to  the 
Tygon tubing. A fte r three m l had been displaced from  the ou tle t chamber, the 
stopcock between the two chambers (C) o f the gradient m ixer was opened. 
Optimal flow  rate was 3 m l/m in  and did not exceed 5 m l/m in . The flow  ra te  was 
regulated so tha t "bombing" of the acrylam ide between the glass plates did not 
occur. Once pouring was complete, 5 m l of d is tilled  water was gently overlayed 
so th a t a stra ight top formed and to  prevent drying out o f the gel top. 
Polym erization was complete w ith in  one hour a fte r which the water was removed 
from  the top of the slab gel and replaced w ith  5 ml of lower gel bu ffe r (Solution 
N:Appendix D) diluted 1:4 w ith  d is tilled  water. The gel was le f t  overnight at 
room temperature.
The fo llow ing day, the stacking gel (4.5% acrylam ide, 0.1% SDS, 0.125M 
T ris -H C l, pH 6.8) su ffic ien t fo r tw o slab gels as shown in Table 6 was prepared. 
The diluted lower gel bu ffe r solution was removed from  the top of the slab gel 
and the gel top ca re fu lly  b lotted dry w ith  bibulous paper. A fte r  the addition of 
the ammonium persulfate and the TEMED, the solution was added between the 
glass plates and f ille d  to  the base of the notch in the beveled plate. The solution 
was care fu lly  overlayed w ith  d is tilled  water to  prevent drying out. 
Polym erization occurred w ith in  one hour.
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TABLE 6
TWO-DIMENSIONAL STACKING GEL
1.5 m l o f acrylam ide (Solution MrAppendix D)
2.5 m l o f upper gel bu ffe r (Solution OiAppendix D)
6 m l o f Abbott Co. d is tilled  water
30 p i o f ammonium persulfate (Solution C:Appendix D) 
10 y l o f TEMED
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Loading O f The Isoe lectric  Focusing Gel Onto The Second Dimension
A fte r  the IEF had been equilib ra ted in the SDS sample bu ffe r (Solution 
P:Appendix D) fo r  45 m in, i t  was ready to  be subjected to  electrophoresis in  the 
second dimension. The w ater covering the stacking gel was removed and the gel 
top b lo tted dry w ith  bibulous paper. An agarose solution (Solution 0 : Appendix 
D) was used to  hold the IEF gel in place between the beveled and rectangular 
plates (Figure 5). This solution also aided in avoiding the m ixing o f protein bands 
when they began to  m igrate  in to  the slab gel. The agarose solution was heated in 
a boiling water bath p rio r to  use. The IEF gel was removed from  the SDS sample 
bu ffe r and placed on a piece o f P a ra film  100 mm x 130 mm. The gel was b lo tted 
dry o f excess SDS sample bu ffe r. One m l of melted agarose solution was poured 
along the top o f the stacking gel and the Parafilm  was used to quickly transfer 
the cy lind rica l gel onto the m elted agarose in the notch (Figure 5). The negative 
end (India ink stab) was to  the le f t  when loading the cy lind rica l gel in to  the notch 
in order to  keep a ll two-dim ensional patterns consistent. The negative end o f the 
gel was placed 10 mm from  the le f t  PVC spacer and was never flushed up against 
the spacer. The gel was then overlayed w ith  1-2 m l o f agarose solution and the 
agarose was allowed to  so lid ify .
Electrophoresis In The Second Dimension
Once the agarose solution had solid ified, there was a space of 15 mm 
between the anodic end o f the cy lind rica l gel tube and the r igh t PVC spacer. A 
spatula was used to  cut a well in to  the agarose 10 mm long and 5 mm deep. This 
agarose cube was discarded so th a t the "mixed buffered m olecular weight 
standards" (Appendix E) could be added. The bottom  pressure bar o f the 
electrophoresis apparatus was removed and the gel was placed in to  the 
e lectrophoretic  tank. Four lite rs  of running bu ffe r (Solution RrAppendix D) was
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Rectangular plain 
or grooved plate
First dimension 
tube gel
Agarose
embedding
medium
Beveled edge
Second 
dimension 
slab gel
(1.5mm)
~ — Beveled glass plate
Figure 5. D iagram m atic cross-sectional representation o f the first-d im ensiona l 
cy lind rica l gel embedded in to  agarose medium in  between the two glass plates 
fo r separation in the second dimension. From: Bio-Rad Laboratories, A p ril, 1978 
Price L is t, p. 125.
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prepared prio r to  use and poured in to  the tank and upper chamber. Bubbles were 
removed from  the bottom  o f the space between the glass plates by streaming 
running bu ffe r between the glass plates using a long Pasteur p ipe tte  crooked at 
the end. The e lectrophore tic  unit was placed in a re fr ig e ra to r a t ^°C  and 100 y l 
o f the "m ixed buffered m olecular weight standards" (See Appendix E) were added 
to  each well cu t in to  the agarose layer. This gave a to ta l protein content of 2.5 y g / 
each m olecular weight m arker. Gels were run a t 6 m illiam ps/gel (constant 
current) fo r  20 hours. Running tim e  varied w ith  the percent of acrylam ide used 
in these experiments; however, th is schedule was su ffic ie n t fo r  a 1096-20% 
polyacrylam ide gradient.
Staining And Destaining O f The Second-Dimensional Gel
Once the e lectrophore tic  run was term inated, the power supply was turned 
o ff and the plates were unclamped from  the e lectrophoretic  apparatus. The PVC 
strips were removed using a laboratory spatula, and the gel plates pried apart by 
constant pressure. The gel was stained a t room tem perature fo r  one hour in stain­
ing solution (Solution T:Appendix D). Following staining, the gel was destained in 
several changes o f destaining solution (Solution U:Appendix D) un til the 
background had a s light t in t  of blue to  enhance the contrast. A fte r  destaining 
was com plete, the gels were placed in a Z iplock "baggie" w ith  7 m l of 
perservative (Solution V:Appendix D) and stored in a re fr ig e ra to r a t 4°C.
Photography
Both firs t-a n d  second-dimensional gels were photographed by using a N ikon- 
F camera w ith  T ri-X  Pan (ASA 32) black and white 35 mm f ilm . The f ir s t ­
dimensional gels were photographed in the tubes w ith  perservative (Solution 
V:Appendix D). Second-dimensional gels were photographed a fte r the stacking 
gel was cut from  the separating gel w ith  a laboratory spatula. A conventional x-
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ray viewing box was placed under the gels during photography. The f  stop was 
set a t 8 and the shutter speed was a t 1/60 sec fo r  the f ir s t -  and second­
dimensional gels.
Gel Density Scanning
First-dimensional gels were scanned on a Beckman Acta  C III 
Spectrophotometer a t 580 nm using a tungsten lamp. A 0.1 mm s lit  was inserted, 
the band w idth was 2 mm and the s lit  w idth was 0.9 mm. A ttenuators were 
inserted in to  the spectrophotometer to  reduce background noise. Gels were 
scanned at 1.5 cm /m in.
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CHAPTER IV 
RESULTS
Comparative U rinary Protein Excretion
Comparative analysis of the urinary protein excretion o f normal donors to 
th a t o f cancer patients revealed th a t the patients w ith  a urogenital dysfunction 
(a benign or m alignant kidney or bladder) demonstrated elevated protein 
concentrations in the urine. The protein concentration of normal urine ranged 
from  5 mg/1 to  62 mg/1 (Table 3) w ith  an average yie ld of 28 mg/1 fo r  normal 
donors. TCC patients, RCC patients, BK patients and BB patients showed 
elevated urinary protein concentrations of 166 mg/1, 95 m g/1, 92 mg/1, and 66 
m g/1, respectively. TCC patients usually had six times more p rec ip ita te  protein 
per l i te r  than did normal donors. Forty  percent of TCC patients and 20% of RCC 
patients demonstrated hematuria or red blood cells in the urinary sediments. 
None of the normal donors, BB, or BK patients demonstrated blood in the urine.
First-D im ensional Separation
Densitom etric scans of the first-d im ensional electrophoregrams of the 
urine from  cancer patients, benign patients, and normal donors are presented in 
figures 6-11. A gel scan of the isoe lectric  focusing gel o f a TCC patient's (Stage 
A -patien t P.P.) urinary proteins is presented in figu re  8 which illus tra tes  the 
problem of some proteins being masked by the diffuse albumin band (pH 6.00- 
6.50). Proteins tha t are seen only in TCC profiles in the second-dimensional gel 
slabs (discussed below) are masked by albumin; however, one unique urinary 
protein associated w ith  TCC was observed outside the area tha t albumin occupies 
in the first-d im ensiona l gel. This protein is shown in figu re  8 as the second
34
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darkly-stained band from  the cathodic end (right side) o f the IEF gel. This 
prote in (to be discussed) has a pi from  6.95-7.50.
Many variations in  pro te in  band patterns th a t are o p tica lly  fa in t in the 
firs t-d im ensiona l gels are revealed in the densitom etric gel scans of the 
isoe lectric  focusing gels. The varia tions are believed to  be associated w ith  the 
random excretion o f urinary proteins, both quan tita tive ly  and qua lita tive ly , as 
well as m inor varia tions in  the genetic makeup o f each patient. In the 
densitom etric scans o f the firs t-d im ension , s im ila rities  in the pi of certa in  
proteins are consistent (e.g. there  is a peak a t all tim es in the pH range 6.25-6.30 
corresponding to  the pi o f albumin). The variations make i t  d if f ic u lt  to  find  
consistency in proteins in decreased concentrations in the urine.
R outinely, no p ro te o ly tic  in h ib ito r was added to  the urine samples; 
however, to  e lim ina te  the possib ility  o f p ro teo ly tic  degradation of urinary 
proteins phenylm ethylsu lfonylfluoride (PMSF), a serine esterase inh ib ito r (35) was 
added to  tw o random urine samples. Urine samples from  K.M . (a RCC patient) 
and W.B. (a TCC patient) were divided in ha lf and the proteins precip ita ted  w ith  
ammonium sulfate. One-half o f each urine was not trea ted  while  the other ha lf 
was trea ted  in the presence o f Im M  PMSF (35). This concentra tion of PMSF was 
kept constant throughout the prote in prec ip ita tion  procedure. D ensitom etric gel 
scans of the IEF gel o f the urine o f a RCC patient (K.M .) are shown in figures 6 
and 7. Figure 6 shows the e lectrophore tic  p ro file  o f the sample trea ted  in the 
presence o f PMSF (densitom etric gel scan-figure 6) whereas figu re  7 
(densitom etric gel scan) shows the urine sample from  this patient tha t was 
concentrated w ithout the addition of PMSF. The firs t-d im ensiona l gels appeared 
to  be s im ila r (figure 12). Most im portan tly , p ro teo ly tic  a c t iv ity  was believed not 
to  have occurred because no "ex tra  spots" were seen in the second-dimensional 
electrophoregram of the urine not trea ted w ith  PMSF (figu re  24).
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The first-d im ensiona l (isoe lectric  focusing) electrophoregrams are 
presented in  figures 12, 13, and 14. Figure 12 shows the rep roduc ib ility  o f an 
identica l urine sample trea ted  rou tine ly  w ith  and w ithout the addition o f a 
protease inh ib ito r. Figure 13 shows the reproducib ility  o f samples run under 
s im ila r conditions; whereas, Figure 14 shows the rep roduc ib ility  o f samples run 
under s im ila r conditions. The resolution o f the first-d im ensiona l gels was lim ite d  
compared to  the two-dimensional polyacrylam ide gel electrophoregrams 
(described below) because separation in the f ir s t  dimension was based on only one 
separation parameter (VIZ the net e lec tr ica l charge of the proteins). Some 
urinary proteins present in low concentrations appeared to  be "masked" by 
proteins in high concentrations or having the same pi.
Second-Dimensional Electrophoresis
The two-dimensional gels were analyzed by comparing the patterns on top 
o f an x-ray  viewing box. W ith few  exceptions, the s im ila rities  o f the gel patterns 
were generally excellent. S im ila r protein patterns were observed fo r  each of the 
d iffe re n t types o f urine samples examined. The higher m olecular weight proteins 
were pore-lim ited  in the upper portion of the gel (1096-15% polyacrylam ide); 
whereas, the proteins w ith  a lower molecular weight m igrated fu rth e r toward the 
bottom  of the gel (1596-20% polyacrylam ide). Molecular weight markers are 
shown separated on the righ t side of the two-dimensional gel p ro files (figures 15- 
25).
Album in was the largest spot in the two-dimensional gel patterns; and was 
in the greatest concentration in most a ll urines tested. Elevated levels of 
albumin were observed in the two-dimensional p ro file  in one o f the two BK 
patients studied. The absence o f an albumin spot in the two-dim ensional profiles 
o f patients A.H. (RCC), R.B. (RCC), G.B. (BB) and P.G. (BK) was observed. 
Furtherm ore, these patients lacked a ll high m olecular weight proteins greater than
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60,000 daltons. On the other hand, 30% of the RCC patients (patients A.D., 
K .M ., and J.O.) and 10% o f the TCC patients (patient G.S.) had protein patterns 
com plete ly devoid of low m olecular weight polypeptides sm aller than 45,000 
daltons. Normal donors demonstrated polypeptides ranging from  11,000 to  85,000 
daltons. Patients w ith  benign diseases (patients G.B. and P.G.) had "smearing" of 
low m olecular weight proteins (10,000 to  45,000 daltons) in the two-dimensional 
p ro file  which was assumed to  be evidence of denaturation.
A ll proteins tha t appeared to  be associated w ith  bladder malignancy had a 
m olecular weight range from  35,000 to  75,000 daltons. A two-dimensional gel 
electrophoregram of the urinary proteins o f patient L.W. (TCC-Stage B) is 
presented in figu re  15. This gel shows four proteins, in section B1 and C l of the 
representative diagram (upper figure) tha t were observed in 80% of a ll TCC 
patients and were not observed in any RCC, BB, BK or normal urine sample. 
These four proteins were d istribu ted linea rly  above the albumin and therefore, 
appear to  have a molecular weight range between 70,000 to  75,000 daltons. The 
pi of these proteins ranged from  6.05-6.25 and always appeared as a te tram er.
The two-dimensional electrophoregram of the urinary proteins o f patient 
E.A. (TCC-Stage D) is presented in figu re  16. A unique polypeptide spot was 
seen in th is p ro file  in section B3 (upper figure) th a t m igrated to a point between 
the 45,000 and 53,000 dalton molecular weight range, a t approxim ately 50,000 
daltons. This protein was more "basic" than the four proteins mentioned above. 
The pi of the polypeptide was between 6.30-6.40 and was present in 6 out o f the 
10 TCC patient two-dimensional patterns. I t  was possible tha t the other four 
TCC patient profiles had this protein, but the concentration in the urine may 
have been below detectable levels. None of the RCC, BK, BB, or normal urines 
demonstrated the presence o f th is prote in in the urine.
A two-dimensional p ro file  of TCC patient G.S. (stage B) is presented in 
figu re  17. A unique protein spot was observed in section A3 of the tw o-
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dimensional pattern  (upper figure). This prote in was seen in 100% of a ll TCC 
patients studied and was undetectable in a ll RCC, BB, BK, and normal urine 
samples. The prote in has an apparent m olecular weight from  35,000-40,000 
daltons w ith  a d iffuse pi ranging from  6.95-7.50. This spot was much la rger (i.e. 
in higher concentration) in urines from  patients w ith  advanced neoplastic 
progression. For example, Stage B TCC patients had a higher concentration o f 
this protein in the ir urine than did a Stage O patient.
A two-dimensional p ro file  o f patient W.J. (Stage B-TCC) is shown in figu re  
18. A 68,000 dalton prote in doublet in section B2 (upper figure) was seen in 40% 
of a ll TCC patient urines. These proteins have a pi from  6.50-6.75 and were 
always present as a dimer. The doublet was not seen in any RCC, BB, BK, or 
normal urine sample.
A two-dimensional p ro file  o f the urine o f pa tien t B.G. (TCC-Stage O) is 
shown in figu re  19. Two proteins approxim ately 53,000 daltons which were 
detected in both TCC and RCC patients are shown in section C3 (upper figure). 
The more basic polypeptide ( le ft spot) electrofocused a t pH 6.10-6.20 whereas 
the more acid ic protein (righ t spot) focused at pH 5.90-6.00 in the f ir s t ­
dimensional gels. These proteins were absent from  normal donor urines and from  
patients w ith  BB and BK diseases. These proteins stained more intensely in TCC 
patient urine electrophoregrams suggesting an increased concentration in TCC 
urines than in RCC urine samples.
The two-dimensional p ro file  of the pooled normal samples from  six age and 
sex-matched normal donors is shown in figu re  20. The unique urinary proteins 
described above were not detected in the normal urine electrophoregrams. As 
described above, these unique proteins were also absent from  electrophoregrams 
of patients w ith  RCC (Figure 21), BK (Figure 22), and BB (Figure 23) regardless 
of the stage of disease.
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The unique proteins regarded as associated w ith  transitiona l ce ll carcinoma 
are summarized in a composite two-dimensional map (figure 25). A lbum in and 
the m olecular weight markers were added fo r  orien ta tion  purposes only. The ten 
urinary proteins shown in th is figu re  are considered to  be possible candidates as 
tumor-associated proteins in transitiona l ce ll carcinoma. The ten proteins 
ranged in isoe lec tric  point from  6.05-7.50 and in the m olecular range from  35,000 
to 75,000 daltons.
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Figure 6. Densitometric gel scan of the isoelectric focusing gel of the urine of
patient K.M . (RCC-Stage D). This gel was treated with the addition of PMSF.
Cathode is toward the right side.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
iiiiiim
iim
m
in
i m
u
n
i
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 7. Densitometric gel scan of the isoelectric focusing gel of the urine of
patient K.M. (RCC-Stage D). This gel was treated without the addition of PMSF.
Cathode is toward the right side.
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Figure 8. Densitometric gel scan of the isoelectric-focusing gel of the urine of
patient P.P. (TCC-Stage A). Cathode is toward the right side.
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Figure 9. Densitometric gel scan of the isoelectric focusing gel of the urine
patient L.P. (BB). Cathode is toward the right side.
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Figure 10. Densitometric gel scan of the isoelectric focusing gel of the urine of
patient P.G. (BK). Cathode is toward the right side.
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Figure 11. Densitometric gel scan of the isoelectric focusing gel of the urine
a normal donor (L.M.). Cathode is toward the right side.
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Figure 12. Isoelectric focusing gels o f the urine of RCC patien t K.M . This 
figure  demonstrates the rep roduc ib ility  between PMSF-treated ( le ft  gel) and 
RMSF-untreated (right gel) urine samples. Cathode is a t the top of the gel.
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Figure 13. Isoe lectric  focusing gels demonstrating the rep roduc ib ility  w ith in  the 
urines o f pathologic and normal donors. From le f t  to  r igh t: patient 3.D. (RCC); 
patient L.P. (BB); normal donor (K.S.); patient P.G. (BK); and patient B.G. (TCC). 
Cathode is toward the top o f the gel.
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Figure 14. Isoe lectric  focusing gels demonstrating the s im ila rities  as w e ll as 
variations between urine samples o f patients w ith  pathologic urines and normal 
donor urines. From le f t  to  r igh t: patient G.8. (BB); pa tien t P.G. (BK); patient 
G.R. (TCC); pa tien t A.H. (RCC) and normal donor (I.S.). Cathode is toward the 
top o f the gel.
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Figure 15. Second dimensional SDS/polyacrylamide gel electrophoregram of the 
urine of pa tien t L.W. (TCC-Stage B). A d iagram m atic representation (top) o f the 
gel slab is divided in to  sections. Four proteins are seen in sections B1 and C l.  A 
photographic reproduction (bottom ) o f the gel slab is shown. M olecular weight 
markers are seen to  the rig h t side of the diagram and photograph. The cathode 
of the f ir s t  dimensional gel is to  the le f t  o f the gel slab.
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Figure 16. Second-dimensional SDS/polyacrylam ide gel electrophoregram of the 
urine o f pa tien t E.A. (TCC-Stage D). A d iagram m atic representation (top) o f the 
gel slab is divided in to  sections. One prote in is seen in section B3. A photographic 
reproduction (bottom ) o f the gel slab is shown. M olecular weight markers are 
seen to  the rig h t side o f the diagram and photograph. The cathode of the f ir s t  
dimensional gel is to  the le f t  of the gel slab.
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Figure 17. Second-dimensional SDS/polyacrylamide gel electrophoregram of the 
urine of patient G.S. (TCC-Stage 3). A diagram m atic representation (top) of the 
gel slab is divided in to  sections. One protein is seen in  section A-3. A photographic 
reproduction (bottom ) o f the gel slab is shown. M olecular weight markers are 
seen to  the righ t side of the diagram and photograph. The cathode of the f ir s t -  
dimensional gel is to  the le f t  o f the gel slab.
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Figure 18. Second-dimensional SDS/polyacrylamide gel electrophoregram of the 
urine o f patient W.J. (TCC-Stage B). A diagram m atic representation (top) o f the 
gel slab is divided in to  sections. Two proteins are seen in section B2. A photo­
graphic reproduction (bottom ) o f the gel slab is shown. M olecular weight 
markers are seen to  the righ t side of the diagram and photograph. The cathode 
of the f ir s t  dimensional gel is to  the le f t  of the gel slab.
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Figure 19. Second-dimensional SDS/polyacrylamide gel electrophoregram of the 
urine o f patient B.G. (TCC-Stage B). A diagram m atic representation (top) o f the 
gel slab is divided in to  sections. Two proteins are seen in section B3. A photo­
graphic reproduction (bottom ) o f the gel slab is shown. M olecular weight 
markers are seen to  the righ t side o f the diagram and photograph. The cathode 
of the f ir s t  dimensional gel is to  the le f t  o f the gel slab.
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Figure 20. Second-dimensional SDS/polyacrylamide gel electrophoregram of the 
urine of six normal donors. A diagram m atic representation (top) of the gel slab 
is divided in to  sections. Notice the absence of the 10 unique proteins associated 
w ith  TCC. A photographic reproduction (bottom) o f the gel slab is shown. 
Molecular weight markers are seen to  the righ t side of the diagram and 
photograph. The cathode of the first-d im ensiona l gel is to  the le f t  of the gel 
slab.
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Figure 21. Second-dimensional SDS/polyacrylamide gel electrophoregram of the 
urine o f patient K .M . (RCC-Stage D). A diagram m atic representation (top) o f 
the gel slab is divided in to  sections. Notice the absence of the 10 unique proteins 
associated w ith  TCC. A photographic reproduction (bottom ) o f the gel slab is 
shown. M olecular weight markers are seen to  the righ t side of the diagram and 
photograph. The cathode of the firs t-d im ensiona l gel is to  the le f t  of the gel 
slab.
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Figure 22. Second-dimensional SDS/polyacrylamide gel electrophoregram of the 
urine o f patient S.B. (BK). A diagram m atic representation (top) of the gel slab is 
divided in to  sections. Notice the absence of the 10 unique proteins associated 
w ith  TCC. A photographic reproduction (bottom) of the gel slab is shown. 
Molecular weight markers are seen to  the righ t side of the diagram and 
photograph. The cathode o f the first-d im ensional gel is to  the le f t  of the gel 
slab.
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Figure 23. Second-dimensional SDS/polyacrylamide gel electrophoregram of the 
urine o f patient L.P. (BB). A d iagram m atic representation (top) o f the gel slab is 
divided in to  sections. Notice the absence of the 10 unique proteins associated 
w ith  TCC. A photographic reproduction (bottom ) of the gel slab is shown. 
Molecular weight markers are seen to  the r igh t side o f the diagram and 
photograph. The cathode o f the first-d im ensiona l gel is to  the le f t  o f the gel 
slab.
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Figure 24. Comparison of the second-dimensional SDS/polyacrylamide gel slabs 
of the urine o f RCC patient K .M . The top figure  represents the urine trea ted  
w ith  Im M  PMSF; whereas, the bottom  photograph is the urine electrophoregram 
w ithout PMSF. Cathode of the first-d im ensiona l gel is toward the le f t  side of 
the gel slab.
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Figure 25. Composite drawing of a two-dimensional electrophoregram showing 
the location of the unique urinary proteins associated w ith  TCC. A lbum in and 
m olecular weight markers are shown fo r  orien ta tion purposes only.
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DISCUSSION
The purpose o f th is investigation was to  determ ine if  unique tum or 
components in the urine o f patients w ith  trans itiona l ce ll carcinoma could be 
detected and characterized (i.e. isoe lec tric  point and m olecular weight) by tw o- 
dimensional polyacrylam ide gel electrophoresis. U rine was chosen as a source of 
unique tum or proteins because the bladder should release in to  the urine soluble 
tumor components associated w ith  malignancy. Because numerous protein 
components in the urine o f renal and bladder patients seem to  be closely re lated 
to  the pathological changes in the gen itourinary tra c t (91, 120), i t  is plausible to 
d iffe ren tia te  various renal and bladder disorders and to  characterize them by 
e lectrophoretic analysis o f proteins in the urine. By characteriz ing these 
components, pu rifica tion  is possible so tha t an immunodiagnostic tes t fo r  early 
detection of bladder cancer may become possible. The specific  assay fo r  the 
detection o f bladder cancer antigens and/or immune complexes can fa c il ita te  
the ir iso lation. However, as in most m alignant disease, the nature of the 
antigens is unknown.
U rinary proteins were concentrated by ammonium su lfa te  p rec ip ita tion  and 
subjected to isoe lectric  focusing in the f ir s t  dimension fo llow ed by 
electrophoresis in a second-dimensional system using SDS/polyacrylamide slab 
gel electrophoresis. One-dimensional isoe lec tric  focusing gels were reproducible 
in the pH range 4.50-6.50. However, the cathodic end (pH 6.50-7.50) of the 
isoe lectric focusing gel showed a sizable varia tion  among gel patterns. L im ited  
in form ation was acquired from  the firs t-d im ensiona l gels; therefore, tw o-
60
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dimensional polyacrylam ide gel electrophoresis (by using tw o d iffe re n t separation 
parameters) made i t  possible to  acquire greater in fo rm ation  about the urinary 
proteins. By varying the concentrations and pH ranges o f the ampholines in the 
f ir s t  dimension and by creating an optim al polyacrylam ide gradient in the second 
dimension, maximum separation and reproducib ility  o f the gels was achieved. 
These percentages o f ampholine and polyacrylam ide were obtained by t r ia l and 
e rro r. V a ria b ility  among firs t-d im ensiona l gels were derived from  using d iffe re n t 
batches o f ampholines (36). D ifferences in normal human antigens, and proteins 
excreted during neoplastic growth and advance of cancer (i.e. stage) from  each 
patient studied contribu ted to  the variations seen when only one means of 
separation was employed.
In an a tte m p t to  m in im ize variations among gel patterns and to  fu rth e r 
id e n tify  the components in urine, two-dimensional electrophoresis was 
perform ed. The c r ite r ia  fo r  using two-dimensional polyacrylam ide gel 
electrophoresis were (1) rep roduc ib ility  of the urine gel patterns, (2) sens itiv ity , 
(3) discreteness o f the prote in spots, and (4) in fo rm ation  obtainable from  the 
protein pattern.
A problem observed w ith  the two-dimensional systems was streaking o f the 
proteins to  the le f t  side (cathodic side) of the two-dimensional 
electrophoregrams. The streaking was noticed to  increase each tim e  the urine 
sample was frozen and thawed. The addition of SDS and 8-ME helped solubilize 
the aggregates th a t were seen in the cathodic end o f the first-d im ensiona l gels.
Regardless o f the lim ita tio n s  and d ifficu ltie s , the results described in th is 
study have iden tified  ten proteins th a t are considered to  be unique components 
present in the urine of patients w ith  transitiona l ce ll carcinoma. Normal urine 
contained from  100-150 polypeptides as demonstrated by the the two-dimensional 
e lectrophore tic  method used in th is  study. S im ila rities  of normal and 
pathological urinary proteins were present in the two-dimensional polyacrylam ide
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gel profiles. By comparing the pi and m olecular weight of each stained
polypeptide in  the polyacrylam ide gel slab, unique components in pathological
urine were id en tified . These proteins were not detected in the urine o f patients 
w ith  BK, BB, and RCC or normal donors. The nature o f the proteins described 
are, to  date, unknown. An absolute determ ination of a tumor-associated
component in  the urine o f patients w ith  TCC cannot be ascertained un til
im m unological tests have been performed (e.g. Ouchterlony assays, fluorescent 
antibody techniques) to  precisely determ ine the spec ific ity . This w ill require 
pu rifica tion  o f the punitive TCC-associated urinary proteins.
Hollinshead, et. a l., (56) have reported a p a rtia lly  purified a 40,000 dalton 
polypeptide in the urine of TCC patients tha t they describe as a bladder cancer 
TAA. I t  is possible tha t th is bladder cancer TAA may be the prote in found in 
section A3 of the upper illu s tra tio n  in figu re  17. This protein occurred in greater 
abundance in patients w ith  advanced stages o f TCC. This protein was not seen in 
any BB, BK, RCC patien t or normal donors; whereas, 100% of the TCC patients 
demonstrated the presence of this protein in th e ir urine. Although the m olecular 
weight of th is  polypeptide is s im ila r to  tha t described by Hollinshead, the 
re lia b ility  of comparing or iden tify ing  proteins based on m olecular weights in 
polyacrylam ide gels is lim ite d  (129).
Rudman, et. a l., (109) describe increased excretion of polypeptides in the 
urine w ith in  the m olecular weight range from  12,000-50,000 daltons in patients 
w ith  advanced neoplastic urogenital disorders. The number and size of the 
urinary proteins demonstrated in the two-dimensional electrophoregrams of TCC 
and RCC patients, as well as in the to ta l protein yie ld (Table 3), confirm s this 
report.
I t  is evident tha t the data obtained in this study has some inherent 
problems associated w ith  the random sample of urines obtained as well as the
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analytica l procedure used. U n til more in form ation and m inor improvements on 
the reproducib ility  and re lia b ility  o f protein patterns is obtained, and the 
in te rp re ta tion  and iden tifica tio n  o f the individual protein components o f urine 
are refined, one should be cautious in calling proteins found in pathological urine 
as tumor-associated components associated w ith  a malignancy. Though certa in  
proteins were found in increased amounts in TCC urine and could not be detected 
in normal, BB, BK, and RCC urines, more sensitive and specific  immunological 
tests fo r  detection w ill be required before these "unique" proteins can be term ed 
"tumor-associated". Nevertheless, the two-dimensional electrophoregrams may 
have m e rit in the in it ia l detection and loca liza tion o f candidate tumor-associated 
urinary proteins.
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APPENDIX C
CHEMICALS
Ampholines were obtained from  Bio-Rad Laboratories (Richmond, C a lif.) as 
Biolytes (40% solids) w ith in  pH range 5 to  7 and pH range 3 to  10. Acrylam ide, 
N,N ' methylene bisacrylam ide (BIS) and sodium dodecyl sulfate (SDS) were also 
purchased from  Bio-Rad Laboratories. Nonidet P-40 (NP-40) was purchased from  
P a rtic le  Data Laboratories (E lmhurst, Ill.)F isher S c ien tific  Co. (Fair Lawn, N.J.) 
supplied the ammonium persulfa te, phosphoric acid, sodium hydroxide, and 
su lfosa licy lic  acid. U ltra  pure urea was purchased from  Schwarz/Mann 
(Orangeburg, N.Y.) Ammonium su lfa te , trich lo roa ce tic  acid (TCA), g lycero l, 
sucrose and N ,N ,N 'N '-te tra-m ethylene diamine (TEMED) were obtained from  
Baker Chemical Co. (Phillipsburg, N.J.) Methanol was supplied by A.H. Thomas 
Co. (Philadelphia, Pa.) M a llincrodt (Paris, Ky.) supplied the acetic  acid. Sigma 
Chemical Co. (St. Louis, Mo.) supplied the 3-mercaptoethanol (S-ME), phenyl- 
m ethylsu lfonylfluo ride (PMSF) and Coomassie B rillia n t Blue R-250 used in these 
experiments. Agarose (SeaKem) was obtained from  Marine Colloids (Rockland, 
Maine). The fo llow ing  m olecular weight markers were used. Molecular weights 
(M.W.) are given in daltons.
MOLECULAR WEIGHT MARKER SUPPLIER
MOLECULAR
WEIGHT
Bovine Serum Album in (BSA) 
Catalase
L-G lu tam ic Dehydrogenase 
Ovalbumin
Pepsin (Hog Stomach) 
Chymotrypsinogen A 
Myoglobin 
Cytochrome c
Calbiochem (San Diego, C a lif.) 68,000
Mann Research (New York, N.Y.) 60,000
Sigma Chemical (St. Louis, Mo.) 53,000
Pharmacia (Piscataway, N.J.) 45,000
Mann Research (New York, N.Y.) 35,000
Pharmacia (Piscataway, N.J.) 25,000
Mann Research (New York, N.Y.) 17,200
Calbiochem (San Diego, C a lif.) 11,700
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APPENDIX D 
REAGENTS, BUFFERS AND SOLUTIONS
A 30% Acrylam ide Stock fo r  IEF Gels: 28.38% (w /v) Acrylam ide and 1.62%
(w /v) BIS. (F ilte red  through Whatman #2 f i l te r  paper and stored in a brown 
glass bo ttle ).
B Stock NP-40 Solution: 10% (w /v) Nonidet P-40 in d is tilled  water. (F ilte red  
through Whatman #2 f i l t e r  paper).
C Ammonium Persulfa te: a 10% (w/v) solution prepared fresh each week.
D Gel O verlay Solution: 8M Urea (stored frozen as 1 m l aliquots).
E SDS Sample Solution: 1% (w /v) SDS in d is tilled  water.
F Lysis Solution: 9.5M Urea, 2% (w /v) NP-40, 2% Ampholines (Comprised 
of 1.6% pH range 5 to  7 and 0.4% pH range 3 to  10). (Stored as frozen 1 
m l aliquots).
G I X  Anode E lectrode Solution: 0.01M H^PO^ (May be prepared as 10 X solution 
and d ilu ted 1:10 before use).
H 1 X Cathode E lectrode Solution: 0.02M NaOH (may be prepared as a 10 
X solution and d ilu ted 1:10 before use).
I Sample Overlay Solution: 9M Urea, 1% Ampholines (Comprised o f 0.8% 
pH range 5 to  7 and 0.2% pH range 3 to  10). (Stored frozen as 1 ml aliquots).
J IEF Gel F ixing Solution: 3.5% (w/v) Su lfosa licy lic  acid, 11.5% (w/v) T rich lo race tic  
acid, 30% (v/v) Methanol.
K IEF Gel Staining Solution: 8% (v/v) A ce tic  Acid, 25% (v/v) Ethanol, 0.2%
(w/v) Coomassie B r illia n t Blue R-250 (F ilte red  through Whatman 1F2. f i l t e r  
paper).
L IEF Gel Destaining Solution: 8% (v/v) A ce tic  Acid, 25% (v /v) Ethanol.
M 30% Acrylam ide Stock fo r  SDS Gels: 29.2% (w /v) Acrylam ide and 0.8% (w /v)
BIS. (F ilte red  through Whatman #2 f i l t e r  paper and stored in a brown glass 
bottle ).
N Lower Gel B u ffe r: 1.5M T ris -H C l, pH 8.8, and 0.4% (w/v) SDS. (F ilte red  
through Whatman 112 f i l t e r  paper).
O Upper Gel B u ffe r: 0.5M T ris -H C l, pH 6.8, and 0.4% (w /v) SDS. (F ilte red  
through Whatman #2 f i l t e r  paper).
P SDS Sample B u ffe r: 10% (w /v) g lycero l, 5% (v/v) 8-mercaptoethanol,
2.3% (w /v) SDS and 0.0625M T ris -H C l, pH 6.8. (F ilte red  through Whatman 
#2 f i l t e r  paper).
O Agarose Gel: 1 gm of agarose melted in  100 m l o f Solution P.
R SDS Running B u ffe r: 0.025M Tris base, 0.192M G lycine, and 0.1% (w /v) SDS 
(prepared prio r to  use).
S B u ffe r For The Preparation O f M olecular Weights: 0.088M T ris -H C l, pH 
6.8.
T Staining Solution fo r  SDS Gels: 25% (w /v) T rich lo roace tic  acid, 0.2% (w /v) 
Coomassie B rillia n t Blue R-250. (F ilte red  through Whatman #2 f i l t e r  paper).
U Destaining Solution fo r  SDS Gels: 7% (v/v) A ce tic  Acid.
V Preservative fo r  IEF and SDS Gels: 5% (v/v) A ce tic  Acid.
W Phosphate-Buffered Saline: 0.35% (w /v) K H ~ P (\,  1.06% (w /v) Na_HPO^*7H_0, 
0.85% (w /v) NaCl, pH 7.3. Z ^ z 4 z
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X B u ffe r fo r M olecular W eight Standards: 0.088M T ris -H C l, pH 6.7.
Solutions A,B,C,D,M ,N,0,P,Q,S,W ,X were stored a t 4 °C.
Solutions G ,H ,J,K ,L,T ,U ,V  were stored a t room tem perature.
A ll other solutions stored as indicated.
Solutions A,B,D,E,F,I,M ,N,0,P,Q ,S should be prepared using Abbott Co. s te rile  
d is tilled  w ater to  m aintain a high level of water pu rity  w ith in  the gel m atrix .
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APPENDIX E
PREPARATION OF MOLECULAR WEIGHT STANDARD
Proteins o f known molecular weights were included in  the protein separation 
in the second dimension. Molecular weight markers used (Appendix C) were 
electrophoresed under s im ilar conditions as the samples. To prepare m olecular 
weight standards, the fo llow ing recipe was prepared in a test tube fo r each 
m olecular weight standard used.
"MOLECULAR WEIGHT STANDARD STOCK"
5 mg of each molecular weight standard was diluted in 1 m l of 50% (w /v) sucrose.
"BUFFERED MOLECULAR WEIGHT STANDARDS"
(200 yg /m l)
40 y l  of 5 m g/m l molecular weight standard stock 
100 y l  o f 1% SDS (Solution E: Appendix D)
100 i l l  of 50% sucrose 
50 y l  of 8-ME
710 y l o f 0.088M T ris -H C l, pH 6.7 (Solution X: Appendix D)
This solution (5% 8-VSE, 0.1% SDS, 0.0625M T ris -H C l, pH 6.7) was boiled 
fo r 3 min and frozen as stored aliquots a t -70°C.
To fa c il ita te  adding the standard to  the second dimensional slab gel, the 
"buffered m olecular weight standards" were mixed by p ipetting 60 y l of each 
buffered standard in to a test tube marked "m ixed buffered molecular weight 
standards". This tube was frozen a t -70°C u n til adding i t  to the well cut in to  the 
agarose gel used in the second dimension.
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